Status:
ACTIVE_NOT_RECRUITING
Platelet-rich Fibrin(PRF) Membrane in Ophthalmic Diseases
Lead Sponsor:
Lei Du
Conditions:
Platelet-rich Fibrin
Macular Holes
Eligibility:
All Genders
20-90 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to observe the role of PRF in treating ophthalmic diseases.The efficacy and safety of PRF were validated for four ophthalmic conditions: macular hole, pterygium, cor...
Detailed Description
Patients suffering from pterygium, macular hole, corneal ulcer, and glaucoma requiring for trabeculectomy , who visited Renmin Hospital of Whuhan University, were chosen to participate in this study. ...
Eligibility Criteria
Inclusion
- Diagnosis of macular hole confirmed by fundus examination;
- Diagnosis of pterygium by slit lamp;
- Patients requiring trabeculectomy for glaucoma;
- Diagnosis of corneal ulcer confirmed by slit lamp.
Exclusion
- Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;
- Previous history of ophthalmic trauma and ophthalmic surgery;
- Recent use of anticoagulant or antiplatelet drugs;
- Combination of serious systemic diseases such as hypertension and diabetes mellitus.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT06200727
Start Date
January 1 2023
End Date
December 31 2025
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Center, Renmin Hospital of Wuhan University
Wuhan, Hubei, China, 430060